A vs ADI Stock Comparison

Scores Breakdown

Metric	A	ADI
📈 Growth	26/30	28/30
💰 Profitability	17/20	18/20
🏦 Financial Health	15/20	18/20
💵 Valuation	16/20	14/20
⚠️ Risk (lower is better)	5/10	5/10
Overall Score	79/100	83/100

Side-by-Side Summaries

A Analysis	ADI Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory Over the eight quarters, ADI demonstrates a clear uptrend in top-line and bottom-line. Revenues rose from about $2.44B in 2024 Q4 to about $4.02B in 2026 Q3, a roughly 64% expansion. Net income to parent grew from about $478M in 2024 Q4 to about $1.34B in 2026 Q3, despite a dip in 2025 Q1, indicating improving profitability and operating leverage. The sequence shows steady quarterly progression and resilience during 2025. 💰 Margins & Cash Flow Gross margin runs in the mid-60s percent across quarters, supporting sustainable returns as revenue scales. Operating income remains robust, with healthy leverage by 2026 Q3. Cash flow from operating activities stayed positive across the period (e.g., around $1.6B in several quarters) even as investing/financing cash flows varied; free cash flow is generally supported by earnings. 🛡️ Balance Sheet & Liquidity Balance sheet is robust: Equity around $33–35B and total assets near $48B, with liabilities around $14B, implying conservative leverage. Current ratio fluctuates above 1, signaling solid liquidity. ⚠️ Key Drivers & Risks Drivers: AI/Data Center demand for precision analog ICs; automotive/industrial end markets. Risks: Semiconductor cyclicality and sensitivity to inventory/price shifts; valuation sensitivity and macro headwinds.

A Analysis

ADI Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Over the eight quarters, ADI demonstrates a clear uptrend in top-line and bottom-line. Revenues rose from about $2.44B in 2024 Q4 to about $4.02B in 2026 Q3, a roughly 64% expansion. Net income to parent grew from about $478M in 2024 Q4 to about $1.34B in 2026 Q3, despite a dip in 2025 Q1, indicating improving profitability and operating leverage. The sequence shows steady quarterly progression and resilience during 2025.

💰 Margins & Cash Flow

Gross margin runs in the mid-60s percent across quarters, supporting sustainable returns as revenue scales. Operating income remains robust, with healthy leverage by 2026 Q3. Cash flow from operating activities stayed positive across the period (e.g., around $1.6B in several quarters) even as investing/financing cash flows varied; free cash flow is generally supported by earnings.

🛡️ Balance Sheet & Liquidity

Balance sheet is robust: Equity around $33–35B and total assets near $48B, with liabilities around $14B, implying conservative leverage. Current ratio fluctuates above 1, signaling solid liquidity.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center demand for precision analog ICs; automotive/industrial end markets.
Risks: Semiconductor cyclicality and sensitivity to inventory/price shifts; valuation sensitivity and macro headwinds.

Similar Companies

AMAT Score: 79 AME Score: 78 ANET Score: 85 GOOGL Score: 80 TMO Score: 75 WAT Score: 74

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"